CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled / 6 target
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Atezolizumab 1,200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04829383
NCT04829383Phase 2CompletedUpdate Overdue (0.1/mo)Completion was 24mo ago
CompareCT.gov

A Phase II Study of Atezolizumab and Bevacizumab in Child-Pugh B7 and B8 Hepatocellular Carcinoma (The AB7 Trial)

Howard S Hochster·interventional·Posted Apr 2, 2021·Updated Jun 16, 2026

In Brief

A Phase 2 clinical trial evaluating Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma. Completed, enrolled 6 participants across 7 sites.

Signals

Enrollment appears stalled

Detailed Summary

This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnresectable Hepatocellular Carcinoma
CountriesUnited States
CollaboratorsGenentech, Inc., Rutgers Cancer Institute of New Jersey

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 2, 2021
Enrollment StartMar 22, 2021
Primary CompletionJun 19, 2024
Study CompletionOct 15, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.3 years ago

Arms & Interventions

Study Treatmentexperimental

Atezolizumab 1,200 mg IV and bevacizumab 15 mg/kg IV every 3 weeks (on day 1 of each 21-day cycle). Treatment will continue until disease progression or development of unacceptable toxicity.

Drug: AtezolizumabDrug: Bevacizumab

Interventions

Atezolizumabdrug

1,200 mg

Bevacizumabdrug

15 mg/kg